Clinical Trial

Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients

Study acronym: MAGMA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-27; most recent amendment 2026-05-28.
Trial Details
NCT Number NCT05933239
Lead Sponsor Universitair Ziekenhuis Brussel
Conditions Non-small Cell Lung Cancer
Enrollment 20 participants
Start Date 2023-03-30
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-01